SURVIVAL ADVANTAGE OF ADJUVANT CHEMOTHERAPY IN HIGH-RISK NODE-NEGATIVE BREAST-CANCER - 10-YEAR ANALYSIS - AN INTERGROUP STUDY

Purpose: Preliminary analysis showed that adjuvant chemotherapy is eff ective in improving disease-free survival (DFS) among high-risk breast cancer patients, This report updates the analysis of the high-risk gr oup and reports the results of the low-risk group. Methods: Patients w ho had undergone a modified radical mastectomy or a total mastectomy w ith low-axillary sampling, with negative axillary nodes and either an estrogen receptor-negative (ER-) tumor of any size or an estrogen rece ptor-positive (ER+) tumor that measured greater than or equal to 3 cm (high-risk) were randomized to receive six cycles of cyclophosphamide, methotrexate, fluorouracil, and prednisone (CMFP) or no further treat ment. Patients with ER+ tumors less than 3 cm (low-risk) were monitore d without therapy. Results: DFS and overall survival (OS) at 10 years were 73% and 81%, respectively, among patients who received chemothera py, as compared with 58% and 71% in the observation group (P = .0006 f or DFS and P = .02 for OS). Chemotherapy was beneficial for patients w ith large tumors, both ER+ and ER-, showing a 10-year DFS of 70% versu s 51% (P = .0009) and OS of 75% versus 65% (P = .06), Ten-year surviva l was 77% among low-risk patients, 85% among premenopausal patients, a nd 73% in the postmenopausal group. Conclusion: The observed 37% reduc tion in risk of recurrence and 34% reduction in mortality risk at 10 y ears, associated with a 15.4% absolute benefit in disease-free stare a nd 10.1% in survival, reaffirm the role of adjuvant chemohormonal ther apy in the management of high-risk node-negative breast cancer. Tumor size remains a significant prognostic factor associated with recurrenc e and survival in the low-risk group. (C) 1998 by American Society of Clinical Oncology.